Pancragon

Pancragon — Pancreas Bioregulator

Pancragon is a Khavinson-class short-chain bioregulator peptide that restores youthful gene expression in pancreas tissue.

Peptide Specifications

Parameter	Value
Sequence	Lys-Glu-Asp-Trp
Mass	548.6 g/mol
Purity	>98.0%
Target Organ	Pancreas

Figure 1: Pancragon Organ-Specific Bioregulation

Tissue-Specific Mechanism

1. Tetrapeptide with tropism for pancreatic islet cells.
2. Restores beta cell gene expression and granule formation.
3. Normalizes glucagon output from alpha cells.
4. Promotes islet cell survival and proliferation.
5. Reduces autoimmune infiltration in T1D models.

Figure 2: Pancreas Regeneration Curve

Research Results

• 1: Preserves pancreatic endocrine function.
• 2: Prevents progressive beta cell exhaustion.
• 3: Restores insulin:glucagon ratio.

Pancreatic Tissue Bioregulator

Pancragon (Lys-Glu-Asp-Trp) is a synthetic tetrapeptide bioregulator targeting pancreatic tissue gene expression, encompassing both endocrine (islets of Langerhans) and exocrine (acinar cell) compartments. Pancreatic function declines with age across both compartments: beta-cell insulin secretory capacity diminishes, alpha-cell glucagon regulation becomes impaired, and exocrine enzyme production decreases (resulting in subclinical maldigestion in up to 40% of elderly individuals). Pancragon addresses these parallel declines through epigenetic restoration of pancreatic cell transcriptional programs.

1. Pancragon modulates beta-cell chromatin at insulin gene (INS) promoter regions, normalizing glucose-stimulated insulin secretion (GSIS) efficiency.
2. PDX1 (pancreatic and duodenal homeobox protein 1) expression is supported—the master transcription factor for beta-cell identity and insulin gene transcription.
3. GLUT2 glucose transporter expression on beta cells is normalized, restoring accurate glucose sensing that triggers appropriate insulin secretion.
4. Acinar cell digestive enzyme gene expression (amylase, lipase, trypsinogen) is upregulated, addressing the subclinical exocrine insufficiency of aging.
5. Anti-apoptotic gene expression in islet cells is enhanced, protecting the limited beta-cell mass from age-related and inflammatory attrition.

Metabolic Research Applications

• Pre-Diabetes: Age-related beta-cell dysfunction is a primary driver of pre-diabetes. Pancragon’s restoration of GSIS may improve glucose tolerance in the pre-diabetic window.
• Exocrine Insufficiency: Subclinical pancreatic exocrine insufficiency is underdiagnosed in elderly populations. Pancragon addresses this often-overlooked component of digestive aging.
• Beta-Cell Preservation: By supporting PDX1 and anti-apoptotic gene expression, Pancragon may help maintain functional beta-cell mass during the pre-diabetic period.
• Combination: Often paired with Svetinorm (liver bioregulator) for comprehensive metabolic organ support protocols.
• Protocol: 1–2 capsules daily for 20–30 days. Courses repeated every 3–6 months. Compatible with glucose monitoring and HbA1c assessment.